EUROBIO : ACCELERATION OF STRATEGIC DEPLOYMENT IN THE FIRST HALF OF 2023
24 Luglio 2023 - 7:45PM
EUROBIO : ACCELERATION OF STRATEGIC DEPLOYMENT IN THE FIRST HALF OF
2023
ACCELERATION OF STRATEGIC
DEPLOYMENT IN THE FIRST HALF OF 2023
- Strong growth in half-year core
business revenues, up 37%
- Successful deployment of the
Group's strategy:
- Share of proprietary products up,
at 30% of revenues
- Continued internationalization,
with 35% of revenues now generated outside of France
- Acquisition of DID in Italy effective as of July 1st, 2023
Paris, July
24, 2023
– 5:45
pm
Eurobio Scientific
(FR0013240934, ALERS, PEA-PME eligible), a leading French group in
in vitro specialty medical diagnostics and life sciences, today
presents its consolidated half-year revenues for the period ending
June 30, 2023.
Strong growth
of core business at
+37%
Eurobio Scientific recorded revenues of €59.1
million for its core business in the first half of 2023. Activities
linked to the detection of COVID were not significant this semester
and are now integrated to the core business (respiratory panels).In
H1 2022, the Group generated sales of €83.6 million. Excluding
non-recurring sales from the COVID business (€40.6m), growth for H1
2023 therefore reached +37%.
On a comparable proforma basis, i.e. excluding
perimeter effects linked to acquisitions and non-recurring items1,
growth of the core business remained dynamic, at +7%.
|
in €m |
H1 2022 |
H1 2023 |
change. / core |
at constant scope |
|
|
TOTAL |
COVID |
core |
|
|
Revenues |
83.6 |
40.6 |
43.0 |
59.1 |
+37% |
+7% |
| unaudited |
|
|
|
|
|
|
|
Successful deployment of the Group's
strategy
The Group is successfully pursuing its strategy
of targeted geographic and technological expansion, with the
ambition of becoming a major international company in the specialty
diagnostics market, providing its customers with a comprehensive
molecular diagnostics offering, including its own solutions and
those of its partners.
- Share of
proprietary products reached 30% of revenues
The share of proprietary products increased to a
high level, representing 30% of revenues (compared to 18% of core
revenues in 2022), thanks in particular to the contribution of
GenDx, consolidated in the Group's financial statements as of
October 1st, 2022.
- Continued
international expansion of the Group
International sales are growing fast,
representing 35% of first-half revenues (against 25% of core
business revenues in 2022). This increase is mainly due to the new
acquisitions made over the past year in Belgium (BMD) and the
Netherlands (GenDx), as well as increasing cross-selling of the
Group's own products.
A new international entity joined the Group on
July 5, 2023. Following approval from the Italian competition
authorities, Eurobio Scientific completed the acquisition of 100%
of the capital of Diagnostic International Distribution SPA
("DID"), a company based in Milano and specialised in the
distribution of in vitro diagnostic tests for infectious diseases
throughout Italy. Effective for accounting purposes as of July 1st,
2023, this transaction opens the doors of the Italian market,
Europe's 3rd largest diagnostics market. DID's core business
(excluding COVID) generated sales of €10 million in 2022.
Outlook
With the confirmation of the strategic
priorities chosen over the last few years, the Eurobio Scientific
Group will continue to expand on its three pillars: the development
of proprietary products, internationalisation and foray into new
markets.
The Group is also pursuing the integration of
its subsidiaries, and has recently made changes to its governance
by setting up a Group Executive Committee.
Next financial meetingH1 2023 results : October
11, 2023, after market closes
|
About Eurobio ScientificEurobio Scientific is a
key player in the field of specialty in vitro diagnostics. It is
involved from research to manufacturing and commercialization of
diagnostic tests in the fields of transplantation, immunology and
infectious diseases, and sells instruments and products for
research laboratories, including biotechnology and pharmaceutical
companies. Through many partnerships and a strong presence in
hospitals, Eurobio Scientific has established its own distribution
network and a portfolio of proprietary products in the molecular
biology field. The Group has approximately 290 employees and four
production units based in the Paris region, in Germany, in the
Netherlands and in the United States, and several affiliates based
in Dorking UK, Sissach Switzerland, Bünde Germany, Antwerp Belgium,
Utrecht in The Netherlands and Milan in Italy.Eurobio Scientific's
reference shareholder is the EurobioNext holding company which
brings together its two directors, Jean-Michel Carle and Denis
Fortier, alongside the "Pépites et Territoires" by AXA &
NextStage AM investment program, managed by NextStage AM. For more
information, please visit: www.eurobio-scientific.comThe company is
publicly listed on the Euronext Growth market in ParisEuronext
Growth BPI Innovation, PEA-PME 150 and Next Biotech indices,
Euronext European Rising Tech label.Symbol: ALERS - ISIN Code:
FR0013240934 - Reuters: ALERS.PA - Bloomberg: ALERS:FP |
|
Contacts |
|
Groupe Eurobio ScientificDenis Fortier, Chairman
and CEOAnne-Sophie Hérelle, Deputy CEO Finance & ITTel. +33(0)
1 69 79 64 80 |
CalyptusMathieu CalleuxInvestors RelationsTel.
+33(1) 53 65 68 68 - eurobio-scientific@calyptus.net |
1 Acquisitions of BMD Belgium in June 2022 and GenDx Netherlands
in October 2022. Growth adjusted for a non-recurring overstocking
effect in anticipation of the discontinuation of a GenDx product in
H1 2022.
- 230724_PR_Eurobio-Scientific_CA_S1_23_EN_DEF
Grafico Azioni Eurobio Scientific (EU:ALERS)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Eurobio Scientific (EU:ALERS)
Storico
Da Apr 2023 a Apr 2024
